C3 Glomerulopathy
C3 glomerulopathy is a rare kidney disease characterized by the abnormal deposition of complement component C3 in the glomeruli, leading to kidney damage and impaired function.
C3 Glomerulopathy: Iptacopan Study
We are studying the long-term safety and effectiveness of iptacopan for individuals with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis. This research aims to understand how well the treatment works in improving kidney health.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Do you have severe heart problems, like advanced heart disease (NYHA class IV)?
- Have you had a fever of 100.4°F (38°C) or higher in the past week?
- Do you have a history of HIV or any other immune system disease?
- Do you have any serious heart rhythm problems that your doctor has warned you about?
- Are you currently dealing with a serious infection, like a bacterial, viral, or fungal infection?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Vseobecna Fakultni Nemocnice V Praze
#1601: Klinika nefrologie
Prague, Czechia
Assistance Publique Hopitaux De Paris
#1003: Service de Néphrologie
Issy-les-Moulineaux, France
Centre Hospitalier Universitaire De Montpellier
#1002: Service de Néphrologie, Dialyse et transplantation rénale
Montpellier, France
Sponsor: Novartis Pharma AG
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.